Exploring and restoring the p53 pathway using the p53 dissociator assay in yeast

Yeast as a Tool in Cancer Research

Volumn , Issue , 2007, Pages 211-232

  Brachmann, Rainer K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649562012     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-5963-6_9     Document Type: Chapter

References (106)

1. Abarzua, P., J. E. LoSardo, M. L. Gubler, and A. Neri. 1995. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res. 55:3490-3494
2. Abarzua, P., J. E. LoSardo, M. L. Gubler, R. Spathis, Y. A. Lu, A. Felix, and A. Neri. 1996. Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene 13:2477-2482
3. Barinaga, M. 1997. From bench top to bedside. Science 278:1036-1039
4. Baroni, T. E., T. Wang, H. Qian, L. R. Dearth, L. N. Truong, J. Zeng, A. E. Denes, S. W. Chen, and R. K. Brachmann. 2004. A global suppressor motif for p53 cancer mutants. Proc. Natl. Acad. Sci. USA in press.
5. Beroud, C., and T. Soussi. 1998. p53 gene mutation: software and database. Nucleic Acids Res. 26:200-204
6. Bischoff, J. R., D. H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J. A. Nye, A. Sampson-Johannes, A. Fattaey, and F. McCormick. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376
7. Boeke, J. D., F. LaCroute, and G. R. Fink. 1984. A positive selection for mutants lacking orotidine-5?-phosphate decarboxylase activity in yeast: 5-fluoro-orotic acid resistance. Mol. Gen. Genet. 197:345-346
8. Bosari, S., G. Viale, P. Bossi, M. Maggioni, G. Coggi, J. J. Murray, and A. K. Lee. 1994. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J. Natl. Cancer Inst. 86:681-687
9. Bosari, S., G. Viale, M. Roncalli, D. Graziani, G. Borsani, A. K. Lee, and G. Coggi. 1995. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am. J. Pathol. 147:790-798
10. Brachmann, R. K., and J. D. Boeke. 1997. Tag games in yeast: the two-hybrid system and beyond. Curr. Opin. Biotechnol. 8:561-568
11. Brachmann, R. K., M. Vidal, and J. D. Boeke. 1996. Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc. Natl. Acad. Sci. USA 93:4091-4095
12. Brachmann, R. K., K. Yu, Y. Eby, N. P. Pavletich, and J. D. Boeke. 1998. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J. 17:1847-1859
13. Bullock, A. N., and A. R. Fersht. 2001. Rescuing the function of mutant p53. Nat. Rev. Cancer 1:68-76
14. Bullock, A. N., J. Henckel, B. S. DeDecker, C. M. Johnson, P. V. Nikolova, M. R. Proctor, D. P. Lane, and A. R. Fersht. 1997. Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl. Acad. Sci. USA 94:14338-4342
15. Bullock, A. N., J. Henckel, and A. R. Fersht. 2000. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19:1245-1256
16. Bykov, V. J. N., N. Issaeva, A. Shilov, M. Hultcrantz, E. Pugacheva, P. Chumakov, J. Bergman, K. G. Wiman, and G. Selivanova. 2002. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8:282-288
17. Candau, R., D. M. Scolnick, P. Darpino, C. Y. Ying, T. D. Halazonetis, and S. L. Berger. 1997. Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity. Oncogene 15:807-816
18. Cariello, N. F., G. R. Douglas, N. J. Gorelick, D. W. Hart, J. D. Wilson, and T. Soussi. 1998. Databases and software for the analysis of mutations in the human p53 gene, human hprt gene and both the lacI and lacZ gene in transgenic rodents. Nucleic Acids Res. 26:198-199
19. Clayman, G. L., A. K. el-Naggar, S. M. Lippman, Y. C. Henderson, M. Frederick, J. A. Merritt, L. A. Zumstein, T. M. Timmons, T. J. Liu, L. Ginsberg, J. A. Roth, W. K. Hong, P. Bruso, and H. Goepfert. 1998. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16:2221-2232
20. Donehower, L. A., and A. Bradley. 1993. The tumor suppressor p53. Biochim. Biophys. Acta 1155:181-205
21. Duncan, S. J., S. Gruschow, D. H. Williams, C. McNicholas, R. Purewal, M. Hajek, M. Gerlitz, S. Martin, S. K. Wrigley, and M. Moore. 2001. Isolation and structure elucidation of chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J. Am. Chem. Soc. 123:554-560
22. Durfee, T., K. Becherer, P. L. Chen, S. H. Yeh, Y. Yang, A. E. Kilburn, W. H. Lee, and S. J. Elledge. 1993. The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit. Genes Dev. 7:555-569
23. Fields, S., and O. Song. 1989. A novel genetic system to detect protein-protein interactions. Nature 340:245-246
24. Fisher, D. E. 1994. Apoptosis in cancer therapy: crossing the threshold. Cell 78:539-542
25. Foster, B. A., H. A. Coffey, M. J. Morin, and F. Rastinejad. 1999. Pharmacological rescue of mutant p53 conformation and function. Science 286:2507-2510
26. Gannon, J. V., and D. P. Lane. 1991. Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature 349:802-806
27. Gibbs, J. B., and A. Oliff. 1994. Pharmaceutical research in molecular oncology. Cell 79:193-198
28. Gottlieb, T. M., and M. Oren. 1996. p53 in growth control and neoplasia. Biochim. Biophys. Acta 1287:77-102
29. Grant, P. A., D. E. Sterner, L. J. Duggan, J. L. Workman, and S. L. Berger. 1998. The SAGA unfolds: convergence of transcription regulators in chromatin-modifying complexes. Trends Cell Biol. 8:193-197
30. Gyuris, J., E. Golemis, H. Chertkov, and R. Brent. 1993. Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell 75:791-803
31. Hainaut, P., T. Hernandez, A. Robinson, P. Rodriguez-Tome, T. Flores, M. Hollstein, C. C. Harris, and R. Montesano. 1998. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 26:205-213
32. Hainaut, P., and M. Hollstein. 2000. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77:81-137
33. Halazonetis, T. D., and A. N. Kandil. 1993. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J. 12:5057-5064
34. Harris, C. C. 1996. p53 tumor suppressor gene: from the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis 17:1187-1198
35. Harris, C. C. 1996. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88:1442-1454
36. Hernandez-Boussard, T., R. Montesano, and P. Hainaut. 1999. Sources of bias in the detection and reporting of p53 mutations in human cancer: analysis of the IARC p53 mutation database. Genet. Anal. 14:229-233
37. Hernandez-Boussard, T., P. Rodriguez-Tome, R. Montesano, and P. Hainaut. 1999. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum. Mutat. 14:1-8
38. Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancers. Science 253:49-53
39. Holowachuk, E. W., and M. S. Ruhoff. 1995. Efficient gene synthesis by Klenow assembly/extension-Pfu polymerase amplification (KAPPA) of overlapping oligonucleotides. PCR Methods Appl. 4:299-302
40. Hupp, T. R., D. P. Lane, and K. L. Ball. 2000. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem. J. 352 Pt 1:1-17
41. Hupp, T. R., D. W. Meek, C. A. Midgley, and D. P. Lane. 1993. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res. 21:3167-3174
42. Hupp, T. R., A. Sparks, and D. P. Lane. 1995. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83:237-245
43. Iwabuchi, K., P. L. Bartel, B. Li, R. Marraccino, and S. Fields. 1994. Two cellular proteins that bind to wild-type but not mutant p53. Proc. Natl. Acad. Sci. USA 91:6098-6102
44. Iwabuchi, K., B. Li, H. F. Massa, B. J. Trask, T. Date, and S. Fields. 1998. Stimulation of p53-mediated transcriptional activation by the p53- binding proteins, 53BP1 and 53BP2. J. Biol. Chem. 273:26061-26068
45. Kastan, M. B., and G. P. Zambetti. 2003. Parc-ing p53 in the cytoplasm. Cell 112: 1-2
46. Kinzler, K. W., and B. Vogelstein. 1994. Cancer therapy meets p53. N. Engl. J. Med. 331:49-50
47. Klotzsche, O., D. Etzrodt, H. Hohenberg, W. Bohn, and W. Deppert. 1998. Cytoplasmic retention of mutant tsp53 is dependent on an intermediate filament protein (vimentin) scaffold. Oncogene 16:3423-3434
48. Knippschild, U., M. Oren, and W. Deppert. 1996. Abrogation of wild-type p53 mediated growth-inhibition by nuclear exclusion. Oncogene 12:1755-1765
49. Ko, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054-1072
50. Kumar, A., Y. Zhao, G. Meng, M. Zeng, S. Srinivasan, L. M. Delmolino, Q. Gao, G. Dimri, G. F. Weber, D. E. Wazer, H. Band, and V. Band. 2002. Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol. Cell. Biol. 22:5801-5812
51. Lane, D. P. 1992. p53, guardian of the genome. Nature 358:15-16
52. Lane, D. P., and S. Benchimol. 1990. p53: oncogene or anti-oncogene? Genes Dev. 4:1-8
53. Lane, D. P., and L. V. Crawford. 1979. T antigen is bound to a host protein in SV40- transformed cells. Nature 278:261-263
54. Lane, D. P., and P. M. Fischer. 2004. Turning the key on p53. Nature 427:789-790
55. Lane, D. P., and P. A. Hall. 1997. MDM2 - arbiter of p53?s destruction. Trends Biochem. Sci. 22:372-4
56. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331
57. Linzer, D. I., and A. J. Levine. 1979. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43-52
58. Lowe, S. W. 1995. Cancer therapy and p53. Curr. Opin. Oncol. 7:547-553
59. Lozano, G., and R. Montes de Oca Luna. 1998. MDM2 function. Biochim. Biophys. Acta 1377:M55-59
60. Luo, R. X., and D. C. Dean. 1999. Chromatin remodeling and transcriptional regulation. J. Natl. Cancer Inst. 91:1288-1294
61. Lutzker, S. G., and A. J. Levine. 1996. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat. Med. 2:804-810
62. Martin, A. C., A. M. Facchiano, A. L. Cuff, T. Hernandez-Boussard, M. Olivier, P. Hainaut, and J. M. Thornton. 2002. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum. Mutat. 19:149-164
63. McCormick, F. 1999. Cancer therapy based on p53. Cancer J. Sci. Am. 5:139-144
64. Milner, J. 1995. DNA damage, p53 and anticancer therapies. Nat. Med. 1:879-880
65. Moll, U. M., M. LaQuaglia, J. Benard, and G. Riou. 1995. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA 92:4407-4411
66. Moll, U. M., A. G. Ostermeyer, R. Haladay, B. Winkfield, M. Frazier, and G. Zambetti. 1996. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell Biol. 16:1126-1137
67. Moll, U. M., G. Riou, and A. J. Levine. 1992. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA 89: 7262-7266
68. Momand, J., and G. P. Zambetti. 1997. Mdm-2: "big brother" of p53. J. Cell Biochem. 64:343-352
69. Murty, V. V., and R. S. Chaganti. 1998. A genetic perspective of male germ cell tumors. Semin. Oncol. 25:133-144
70. Neil, J. C., E. R. Cameron, and E. W. Baxter. 1997. p53 and tumour viruses: catching the guardian off-guard. Trends Microbiol. 5:115-120
71. Nielsen, L. L., and D. C. Maneval. 1998. P53 tumor suppressor gene therapy for cancer. Cancer Gene. Ther. 5:52-63
72. Niewolik, D., B. Vojtesek, and J. Kovarik. 1995. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 10:881-890
73. Nigro, J. M., S. J. Baker, A. C. Preisinger, J. M. Jessup, R. Hostetter, K. Cleary, S. H. Bigner, N. Davidson, S. Baylin, P. Devilee, T. Glover, F. S. Collins, A. Weslon, R. Modali, C. C. Harris, and B. Vogelstein. 1989. Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705-708
74. Nikolaev, A. Y., M. Li, N. Puskas, J. Qin, and W. Gu. 2003. Parc: a cytoplasmic anchor for p53. Cell 112:29-40
75. Nikolova, P. V., K. B. Wong, B. DeDecker, J. Henckel, and A. R. Fersht. 2000. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J. 19:370-378
76. Ogryzko, V. V., T. Kotani, X. Zhang, R. L. Schlitz, T. Howard, X. J. Yang, B. H. Howard, J. Qin, and Y. Nakatani. 1998. Histone-like TAFs within the PCAF histone acetylase complex. Cell 94:35-44
77. Olivier, M., R. Eeles, M. Hollstein, M. A. Khan, C. C. Harris, and P. Hainaut. 2002. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19:607-614
78. Pina, B., S. Berger, G. A. Marcus, N. Silverman, J. Agapite, and L. Guarente. 1993. ADA3: a gene, identified by resistance to GAL4-VP16, with properties similar to and different from those of ADA2. Mol. Cell. Biol. 13:5981-5989
79. Prives, C., and P. A. Hall. 1999. The p53 pathway. J. Pathol. 187:112-126
80. Raj, K., P. Ogston, and P. Beard. 2001. Virus-mediated killing of cells that lack p53 activity. Nature 412:914-917
81. Raman, V., S. A. Martensen, D. Reisman, E. Evron, W. F. Odenwald, E. Jaffee, J. Marks, and S. Sukumar. 2000. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 405:974-978
82. Rippin, T. M., V. J. Bykov, S. M. Freund, G. Selivanova, K. G. Wiman, and A. R. Fersht. 2002. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21:2119-2129
83. Roth, J. A., D. Nguyen, D. D. Lawrence, B. L. Kemp, C. H. Carrasco, D. Z. Ferson, W. K. Hong, R. Komaki, J. J. Lee, J. C. Nesbitt, K. M. Pisters, J. B. Putnam, R. Schea, D. M. Shin, G. L. Walsh, M. M. Dolormente, C. I. Han, F. D. Martin, N. Yen, K. Xu, L. C. Stephens, T. J. McDonnell, T. Mukhopadhyay, and D. Cai. 1996. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2:985-991
84. Scheffner, M., U. Nuber, and J. M. Huibregtse. 1995. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373:81-83
85. Schlamp, C. L., G. L. Poulsen, T. M. Nork, and R. W. Nickells. 1997. Nuclear exclusion of wild-type p53 in immortalized human retinoblastoma cells. J. Natl. Cancer Inst. 89:1530-1536
86. Selivanova, G., V. Iotsova, I. Okan, M. Fritsche, M. Strom, B. Groner, R. C. Grafstrom, and K. G. Wiman. 1997. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3:632-638
87. Stoll, R., C. Renner, S. Hansen, S. Palme, C. Klein, A. Belling, W. Zeslawski, M. Kamionka, T. Rehm, P. Muhlhahn, R. Schumacher, F. Hesse, B. Kaluza, W. Voelter, R. A. Engh, and T. A. Holak. 2001. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40:336-344
88. Stommel, J. M., N. D. Marchenko, G. S. Jimenez, U. M. Moll, T. J. Hope, and G. M. Wahl. 1999. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18:1660-1672
89. Struhl, K. 1998. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12:599-606
90. Struhl, K., and Z. Moqtaderi. 1998. The TAFs in the HAT. Cell 94:1-4
91. Sun, X. F., J. M. Carstensen, H. Zhang, O. Stal, S. Wingren, T. Hatschek, and B. Nordenskjold. 1992. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340:1369-1373
92. Swisher, S. G., J. A. Roth, J. Nemunaitis, D. D. Lawrence, B. L. Kemp, C. H. Carrasco, D. G. Connors, A. K. El-Naggar, F. Fossella, B. S. Glisson, W. K. Hong, F. R. Khuri, J. M. Kurie, J. J. Lee, J. S. Lee, M. Mack, J. A. Merritt, D. M. Nguyen, J. C. Nesbitt, R. Perez-Soler, K. M. Pisters, J. B. Putnam, Jr., W. R. Richli, M. Savin, D. S. Schrump, D. M. Shin, A. Shylkin, G. L. Walsh, J. Wait, D. Weill, and M. K. A. Waugh. 1999. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 91:763-771
93. Takimoto, R., W. Wang, D. T. Dicker, F. Rastinejad, J. Lyssikatos, and W. S. El-Deiry. 2002. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol. Therapy 1:in press.
94. Vassilev, L. T., B. T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, and E. A. Liu. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848
95. Vidal, M., R. K. Brachmann, A. Fattaey, E. Harlow, and J. D. Boeke. 1996. Reverse two-hybrid and one-hybrid systems to detect dissociation of protein-protein and DNA- protein interactions. Proc. Natl. Acad. Sci. USA 93:10315-10320
96. Vogelstein, B., and K. W. Kinzler. 1992. p53 function and dysfunction. Cell 70:523-526
97. Vogelstein, B., D. Lane, and A. J. Levine. 2000. Surfing the p53 network. Nature 408:307-310
98. Vousden, K. H. 2000. p53: death star. Cell 103:691-694
99. Waddell, S., and J. R. Jenkins. 1998. Defining the minimal requirements for papilloma viral E6-mediated inhibition of human p53 activity in fission yeast. Oncogene 16: 1759-1765
100. Wang, M. M., and R. R. Reed. 1993. Molecular cloning of the olfactory neuronal transcription factor Olf-1 by genetic selection in yeast. Nature 364:121-126
101. Wang, T., T. Kobayashi, R. Takimoto, A. E. Denes, E. L. Snyder, W. S. El-Deiry, and R. K. Brachmann. 2001. hADA3 is required for p53 activity. EMBO J. 20:6404-6413
102. Weiss, J., M. Heine, B. Korner, H. Pilch, and E. G. Jung. 1995. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications. Br. J. Dermatol. 133:23-31
103. White, M. A. 1996. The yeast two-hybrid system: forward and reverse. Proc. Natl. Acad. Sci. USA 93:10001-10003
104. Wieczorek, A. M., J. L. Waterman, M. J. Waterman, and T. D. Halazonetis. 1996. Structure-based rescue of common tumor-derived p53 mutants. Nat. Med. 2:1143-1146
105. Wolf, J. K., G. B. Mills, L. Bazzet, R. C. Bast, Jr., J. A. Roth, and D. M. Gershenson. 1999. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol. Oncol. 75:261-266
106. Wong, K. B., B. S. DeDecker, S. M. Freund, M. R. Proctor, M. Bycroft, and A. R. Fersht. 1999. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc. Natl. Acad. Sci. USA 96:8438-8442.